4887-95-0

Basic information

• Product Name: 2,5-DICHLOROBENZIMIDAZOLE
• Synonyms: 2,5-DICHLOROBENZIMIDAZOLE;1H-Benzimidazole,2,5-dichloro-(9CI);2,5-DICHLORO-1H-BENZIMIDAZOLE;2,5-Dichloro-1H-benzoiMidazole;2,5-dichloro-1H-1,3-benzodiazole;2,6-dichloro-1H-1,3-benzodiazole;2,6-Dichloro-1H-benzimidazole;2,6-Dichloro-1H-benzo[d]iMidazole
• CAS NO: 4887-95-0
• Molecular Formula: C₇H₄Cl₂N₂
• Molecular Weight: 187.03
• Product Categories: BENZIMIDAZOLE
• Mol File: 4887-95-0.mol
• Article Data: 10

Chemical Properties

• Melting Point: 207-208 °C (decomp)
• Boiling Point: 364.5 °C at 760 mmHg
• Flash Point: 205.7 °C
• Appearance: /
• Density: 1.571 g/cm³
• Vapor Pressure: 1.68E-05mmHg at 25°C
• Refractive Index: 1.708
• Storage Temp.: 2-8°C
• PKA: 8.11±0.10(Predicted)
• CAS DataBase Reference: 2,5-DICHLOROBENZIMIDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,5-DICHLOROBENZIMIDAZOLE(4887-95-0)
• EPA Substance Registry System: 2,5-DICHLOROBENZIMIDAZOLE(4887-95-0)

Safety Data

• Hazardous Substances Data: 4887-95-0(Hazardous Substances Data)

Usage

General Description

2,5-Dichlorobenzimidazole is a chemical compound with the molecular formula C7H4Cl2N2. It is a white to off-white powder that is sparingly soluble in water. 2,5-DICHLOROBENZIMIDAZOLE is commonly used as a reagent in organic synthesis and as an intermediate in the production of other chemicals. It is also used as a corrosion inhibitor in industrial processes and as a fungicide in agriculture. Some studies have shown that 2,5-Dichlorobenzimidazole may have potential toxicity to aquatic organisms and may have harmful effects on human health if ingested or inhaled in large quantities. Therefore, proper safety precautions should be taken when handling this chemical.

InChI:InChI=1/C7H4Cl2N2/c8-4-1-2-5-6(3-4)11-7(9)10-5/h1-3H,(H,10,11)

Upstream product

• 2034-23-3 5-chloro-1,3-dihydrobenzoimidazol-2-one 
• 95-83-0 4-Chloro-1,2-phenylenediamine 
• 40828-56-6 5(6)-Chlorobenzimidazole-2-sulfonic acid 
• 25369-78-2 5-chloro-1,3-dihydro-2H-benzo[d]imidazole-2-thione 
• 4857-06-1 2-chloro-1H-benzoimidazole 

Downstream Products

• 24752-26-9 (5-chloro-1⁽³⁾H-benzoimidazol-2-yl)-(4-chloro-phenyl)-amine 
• 86601-38-9 (5-chloro-1⁽³⁾H-benzoimidazol-2-yl)-phenyl-amine 
• 1049798-98-2 5⁽⁶⁾-chloro-2-(3-chloro-4-fluoroanilino)-1H-benzimidazole hydrochloride 
• 1049799-17-8 5⁽⁶⁾-chloro-2-(4-trifluoromethylanilino)-1H-benzimidazole hydrochloride 
• 1073558-72-1 8-(6-chloro-1H-benzimidazol-2-yl)-3-phenyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one trifluoroacetate 
• 1012331-88-2 C₂₅H₂₀Cl₂FN₅O 
• 401567-04-2 3-{(2S,4S)-1-benzyloxycarbonyl-4-[4-(5-chlorobenzimidazol-2-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl}thiazolidine 
• 1453097-56-7 C₂₂H₁₅ClN₄O 
• 1453097-15-8 1-(5-chloro-1H-benzimidazol-2-yl)-3-methyl-4-(phenylmethyl)-1H-pyrazol-5-ol 
• 99122-11-9 5-chloro-2-hydrazino-1H-benzimidazole 
• 1197337-91-9 C₁₆H₁₃ClN₄O 
• 5418-93-9 6-chloro-1H-benzoimidazol-2-amine 
• 95-83-0 4-Chloro-1,2-phenylenediamine 

Relevant articles and documents

Benzimidazole derivatives, their preparation and their application in medicine and pharmacology (by machine translation)

The invention relates to a new control or inhibit indocyanine 2, 3 - dioxygenase (IDO) activity of the benzimidazole derivatives, their preparation and their application in medicine and pharmacology. Specifically, the invention relates to a compound of general formula (I) compound of formula and its pharmaceutically acceptable salt, containing the compound or its pharmaceutically acceptable salt of the pharmaceutical composition, the use of the compound or its pharmaceutically acceptable salts for treating and/or preventing the relevance of the IDO-mediated disease, especially a tumor of the method and the compound or its pharmaceutically acceptable salts thereof. The invention also relates to the compound or its pharmaceutically acceptable salt or containing the compound or its pharmaceutically acceptable salts for the preparation of a pharmaceutical composition for treating and/or preventing the relevance of the IDO-mediated disease, in particular of the use of the drug in the tumor. Wherein the general formula (I) of each substituent is as defined in the specification. (by machine translation)

Design and synthesis of prostate cancer antigen-1 (PCA-1/ALKBH3) inhibitors as anti-prostate cancer drugs

A series of 1-aryl-3,4-substituted-1H-pyrazol-5-ol derivatives was synthesized and evaluated as prostate cancer antigen-1 (PCA-1/ALKBH3) inhibitors to obtain a novel anti-prostate cancer drug. After modifying 1-(1H-benzimidazol-2-yl)-3,4-dimethyl-1H-pyrazol-5-ol (1), a hit compound found during random screening using a recombinant PCA-1/ALKBH3, 1-(1H-5- methylbenzimidazol-2-yl)-4-benzyl-3-methyl-1H-pyrazol-5-ol (35, HUHS015), was obtained as a potent PCA-1/ALKBH3 inhibitor both in vitro and in vivo. The bioavailability (BA) of 35 was 7.2% in rats after oral administration. As expected, continuously administering 35 significantly suppressed the growth of DU145 cells, which are human hormone-independent prostate cancer cells, in a mouse xenograft model without untoward effects.

Design, syntheses, and structure-activity relationships of novel NPY Y5 receptor antagonists: 2-{3-Oxospiro[isobenzofuran-1(3H),4′-piperidin]-1′-yl}benzimidazole derivatives

Design, syntheses, and structure-activity relationships of a novel class of 2-{3-oxospiro[isobenzofuran-1(3H),4′-piperidin]-1′-yl}benzimidazole NPY Y5 receptor antagonists are described. The benzimidazole structures were newly designed based on the urea linkage of our prototype Y5 receptor antagonists (2 and 3). By optimizing substituents on the benzimidazole core part of the lead compound 5a, we were able to develop a potent, orally available, and brain-penetrable Y5 selective antagonist (5k). Crown Copyright